Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system

Lung Cancer

Volumn 58, Issue 2, 2007, Pages 196-204

  Kirstein, Mark N ^a,b   Wieman, Katie M ^a   Williams, Brent W ^a   Fisher, James E ^a,b   Marker, Paul H ^c   Le, Chap T ^b   Yee, Douglas ^b,c   Kratzke, Robert A ^b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Bioreactor; Continuous infusion; Gemcitabine; H2009 cells; Non small cell lung cancer; Pharmacokinetics

Indexed keywords

GEMCITABINE; NUCLEOSIDE ANALOG; RIBONUCLEOTIDE REDUCTASE; TRYPAN BLUE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOREACTOR; CELL CULTURE; CELL CYCLE; CELL GROWTH; CELL SURVIVAL; CLONOGENIC ASSAY; CONTINUOUS INFUSION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; NICK END LABELING; PRIORITY JOURNAL;

APOPTOSIS; BIOREACTORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CULTURE TECHNIQUES; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; LUNG NEOPLASMS; TIME FACTORS; TUMOR STEM CELL ASSAY;

EID: 34848827487     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.06.005     Document Type: Article

References (42)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 1 (2007) 43-66
2. Strauss, GM, Herndon J, Maddaus MA, Johnstone DW, Johnson D, Watson EA et al., Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. Proceedings of the American Society of Cinical Oncology, 2004;22:p. 621s.
3. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., and Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 4 (2004) 351-360
4. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 25 (2005) 2589-2597
5. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 24 (2006) 2542-2550
6. Gallo J.M., Vicini P., Orlansky A., Li S., Zhou F., Ma J., et al. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clin Cancer Res 10 23 (2004) 8048-8058
7. Suggitt M., and Bibby M.C. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 11 3 (2005) 971-981
8. Chou T.C., Motzer R.J., Tong Y., and Bosl G.J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86 20 (1994) 1517-1524
9. Zamboni W.C., Houghton P.J., Hulstein J.L., Kirstein M., Walsh J., Cheshire P.J., et al. Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemother Pharmacol 43 4 (1999) 269-276
10. Stewart C.F., Iacono L.C., Chintagumpala M., Kellie S.J., Ashley D., Zamboni W.C., et al. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol 22 16 (2004) 3357-3365
11. Markman M., Rose P.G., Jones E., Horowitz I.R., Kennedy A., Webster K., et al. Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens. J Clin Oncol 16 5 (1998) 1849-1851
12. de Gramont A., Bosset J.F., Milan C., Rougier P., Bouche O., Etienne P.L., et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15 2 (1997) 808-815
13. Kellie S.J., Koopmans P., Earl J., Nath C., Roebuck D., Uges D.R., et al. Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors. Cancer 100 12 (2004) 2637-2643
14. Clark P.I., Slevin M.L., Joel S.P., Osborne R.J., Talbot D.I., Johnson P.W., et al. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 12 7 (1994) 1427-1435
15. Tempero M., Plunkett W., Ruiz Van Haperen V., Hainsworth J., Hochster H., Lenzi R., et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21 18 (2003) 3402-3408
16. Kirstein M.N., Houghton P.J., Cheshire P.J., Richmond L.B., Smith A.K., Hanna S.K., et al. Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res 7 2 (2001) 358-366
17. Kirstein M.N., Brundage R.C., Elmquist W.F., Remmel R.P., Marker P.H., Guire D.E., et al. Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. Breast Cancer Res Treat 96 3 (2006) 217-225
18. Ibrahim K.H., Hovde L.B., Ross G., Gunderson B., Wright D.H., and Rotschafer J.C. Microbiologic effectiveness of time- or concentration-based dosing strategies in Streptococcus pneumoniae. Diagn Microbiol Infect Dis 44 3 (2002) 265-271
19. Bilello J.A., Bauer G., Dudley M.N., Cole G.A., and Drusano G.L. Effect of 2′,3′-didehydro-3′-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob Agents Chemother 38 6 (1994) 1386-1391
20. Mackey J.R., Mani R.S., Selner M., Mowles D., Young J.D., Belt J.A., et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58 19 (1998) 4349-4357
21. Krishnan P., Fu Q., Lam W., Liou J.Y., Dutschman G., and Cheng Y.C. Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of l-nucleoside analog diphosphates by 3-phosphoglycerate kinase. J Biol Chem 277 7 (2002) 5453-5459
22. Heinemann V., Xu Y.Z., Chubb S., Sen A., Hertel L.W., Grindey G.B., et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38 4 (1990) 567-572
23. Plunkett W., Huang P., and Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 6 Suppl 6 (1995) 7-13
24. Abbruzzese J.L., Grunewald R., Weeks E.A., Gravel D., Adams T., Nowak B., et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9 3 (1991) 491-498
25. Venook A.P., Egorin M.J., Rosner G.L., Hollis D., Mani S., Hawkins M., et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and leukemia group B 9565. J Clin Oncol 18 14 (2000) 2780-2787
26. Kroep J.R., Giaccone G., Voorn D.A., Smit E.F., Beijnen J.H., Rosing H., et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 17 7 (1999) 2190-2197
27. Jacobson B.A., Alter M.D., Kratzke M.G., Frizelle S.P., Zhang Y., Peterson M.S., et al. Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res 66 8 (2006) 4256-4262
28. Kirstein M.N., Hassan I., Guire D.E., Weller D.R., Dagit J.W., Fisher J.E., et al. High-performance liquid chromatographic method for the determination of gemcitabine and 2′,2′-difluorodeoxyuridine in plasma and tissue culture media. J Chromatogr B Analyt Technol Biomed Life Sci 835 1-2 (2006) 136-142
29. Kirstein M.N., Brundage R.C., Moore M.M., Williams B.W., Hillman L.A., Dagit J.W., et al. Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system. Cancer Chemother Pharmacol (2007)
30. Visaria R.K., Griffin R.J., Williams B.W., Ebbini E.S., Paciotti G.F., Song C.W., et al. Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-alpha delivery. Mol Cancer Ther 5 4 (2006) 1014-1020
31. Rajdev L., Goldberg G., Hopkins U., and Sparano J.A. A phase I trial of gemcitabine administered as a 96-h continuous intravenous infusion in patients with advanced carcinoma and lymphoma. Med Oncol 23 3 (2006) 369-376
32. Cappuzzo F., Novello S., De Marinis F., Selvaggi G., Scagliotti G.V., Barbieri F., et al. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer 52 3 (2006) 319-325
33. Achiwa H., Oguri T., Sato S., Maeda H., Niimi T., and Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 95 9 (2004) 753-757
34. Bergman A.M., Pinedo H.M., Talianidis I., Veerman G., Loves W.J., van der Wilt C.L., et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer 88 12 (2003) 1963-1970
35. Hubeek I., Peters G.J., Broekhuizen A.J., Talianidis I., Sigmond J., Gibson B.E., et al. Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours. J Clin Pathol 58 7 (2005) 695-699
36. Oguri T., Achiwa H., Sato S., Bessho Y., Takano Y., Miyazaki M., et al. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol Cancer Ther 5 7 (2006) 1800-1806
37. Davidson J.D., Ma L., Flagella M., Geeganage S., Gelbert L.M., and Slapak C.A. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 64 11 (2004) 3761-3766
38. Amler L.C., Goddard A.D., and Hillan K.J. Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors. Cold Spring Harb Symp Quant Biol 70 (2005) 483-488
39. Endo K., Konishi A., Sasaki H., Takada M., Tanaka H., Okumura M., et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 50 3 (2005) 375-384
40. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 9 (1999) 2639-2648
41. Joffe S., and Miller F.G. Rethinking risk-benefit assessment for phase I cancer trials. J Clin Oncol 24 19 (2006) 2987-2990
42. Ratain M.J., Eisen T., Stadler W.M., Flaherty K.T., Kaye S.B., Rosner G.L., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 16 (2006) 2505-2512